isoniazid

By Targets:	Antibiotic (4) Autophagy (4) Bacterial (9) Drug Metabolite (2) Endogenous Metabolite (2) Mitophagy (4) Phosphodiesterase (PDE) (1)
By Research Areas:	Infection (11) Inflammation/Immunology (2) Neurological Disease (1)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B0329

*Isoniazid* 3 Publications Verification INH; Isonicotinic acid hydrazide; Isonicotinic hydrazide	Bacterial Autophagy Mitophagy Antibiotic	Infection
Isoniazid (INH) is a proagent and must be activated by a bacterial catalase-peroxidase enzyme KatG. Isoniazid is bactericidal to rapidly dividing mycobacteria and has anti-tuberculostatic activity .

HY-B0329S

Isoniazid-d4 INH-d₄; Isonicotinic acid hydrazide-d₄; Isonicotinic hydrazide-d₄	Bacterial Autophagy Mitophagy Antibiotic	Infection
Isoniazid-d₄ is the deuterium labeled Isoniazid. Isoniazid (INH) is a proagent and must be activated by a bacterial catalase-peroxidase enzyme KatG. Isoniazid is bactericidal to rapidly dividing mycobacteria and has anti-tuberculostatic activity[1][2][3][4].

HY-B0329R

Isoniazid (Standard)	Bacterial Autophagy Mitophagy Antibiotic	Infection
Isoniazid (Standard) is the analytical standard of Isoniazid. This product is intended for research and analytical applications. Isoniazid (INH) is a proagent and must be activated by a bacterial catalase-peroxidase enzyme KatG. Isoniazid is bactericidal to rapidly dividing mycobacteria and has anti-tuberculostatic activity .

HY-158289

Isoniazid-KLH	Antibiotic Mitophagy Autophagy Bacterial	Infection
Isoniazid-KLH is one of protein/peptide and small molecule drug conjugates (PDCs), consisting of Isoniazid (HY-B0329) and KLH. PCDs are promising targeted therapeutics with better cell permeability and drug selectivity than antibody-drug conjugates (ADCs). PDCs have been widely used in research on cancer, COVID-19, and metabolic diseases .

HY-117492

Aconiazide

Isonicophen
Others Infection

Aconiazide (Isonicophen) is a orally active hydrazone derivative of isoniazid, and can be used for study of tuberculosis .

Aconiazide Isonicophen	Others	Infection
Aconiazide (Isonicophen) is a orally active hydrazone derivative of isoniazid, and can be used for study of tuberculosis .

HY-157870

Mtb-IN-6	Bacterial	Infection
Mtb-IN-6 (Compound C10) is a Mycobacterium tuberculosis(*Mtb) respiration inhibitor. Mtb-IN-6 can enhance the bactericidal activity of isoniazid* (INH, HY-B0329). Mtb-IN-6 inhibits WT Mtb with an IC₅₀ of 25 µM .

HY-101059

FGIN 1-27	Others	Neurological Disease
FGIN 1-27, an indoleacetamide, is a specific peripheral benzodiazepine receptor (PBR) ligand with a K_i of 5.0 nM. FGIN 1-27 can penetrate the blood brain barrier (BBB). FGIN 1-27 inhibits the onset of Isoniazid-induced convulsions .

HY-I0736

Isonicotinic acid	Drug Metabolite Endogenous Metabolite	Others
Isonicotinic acid is a metabolite of Isoniazid. Isoniazid is converted to Isonicotinic acid by hydrazinolysis, with the Isoniazid to Isonicotinic acid biotransformation also to be catalyzed by cytochrome P450 (CYP) enzymes, e.g., CYP2C .

HY-I0736S

Isonicotinic acid-d4	Drug Metabolite Endogenous Metabolite	Others
Isonicotinic acid-d₄ is the deuterium labeled Isonicotinic acid[1]. Isonicotinic acid is a metabolite of Isoniazid. Isoniazid is converted to Isonicotinic acid by hydrazinolysis, with the Isoniazid to Isonicotinic acid biotransformation also to be catalyzed by cytochrome P450 (CYP) enzymes, e.g., CYP2C[2].

HY-147263

Dovramilast CC-11050	Phosphodiesterase (PDE)	Infection Inflammation/Immunology
Dovramilast (CC-11050) is an orally active phosphodiesterase 4 (PDE4) inhibitor and can reduce the inflammatory response and improves Isoniazid (INH)-mediated bacillary clearance from the lungs. Dovramilast, as an adjunct, is used for the research of tuberculosis (TB) .

HY-129943

Benzothiohydrazide	Bacterial	Infection
Benzothiohydrazide is an analogue of anti–tubercular agent Isoniazid. Benzothiohydrazide exhibits anti–tubercular activity, with MICs of 132 μM and 264 μM for M. tuberculosis wild type (H37Rv) and clinical mutant strains (IC₁ and IC₂) .

HY-155722

Mtb-IN-5	Bacterial	Infection
Mtb-IN-5 (compound (-)17j) is an isoxazole, with anti-Mycobacterium tuberculosis (Mtb) activity. Mtb-IN-4 inhibits Mtb respiration and biofilm formation in macrophage, and enhances antibiotic isoniazid (INH) inhibition against INH-resistant Mtb mutant .

HY-155720

Mtb-IN-4	Bacterial	Infection
Mtb-IN-4 (compound 17h) is a nontoxic isoxazole, with anti-Mycobacterium tuberculosis (Mtb) activity (IC₅₀=0.70 μM). Mtb-IN-4 inhibits Mtb respiration and biofilm formation in macrophage, and enhances antibiotic isoniazid (INH) inhibition against INH-resistant Mtb mutant .

HY-158380

UH-NIP-16	Bacterial	Infection
UH-NIP-16 exhibits antimicrobial activity against Mycobacterium tuberculosis, with MIC₅₀ of 1.86 and 3.05 μM, for pathogenic mycobacterial strains H37Rv and CDC1551. UH-NIP-16 synergizes with Streptomycin (HY-B1906), Isoniazid (HY-B0329), Ethambutol (HY-B0535) and Bedaquiline (HY-14881), potentiates their anti-tuberculosis activities .

Cat. No.	Product Name

HY-L142

Anti-tuberculosis Compound Library	95 compounds
Tuberculosis (TB), usually caused by bacteria (Mycobacterium tuberculosis), is an infectious disease that mainly affects the lungs. According to the statistics of the World Health Organization (WHO), 10 million people suffer from tuberculosis every year, and 1.5 million people die of tuberculosis every year, which makes tuberculosis the number one killer of infectious diseases. Tuberculosis can be cured through the standard 6-month course of treatment of four kinds of antibiotics. Common drugs include rifampicin and isoniazid. In some cases, TB bacteria do not respond to standard drugs, that is, patients with drug-resistant tuberculosis. The treatment of drug-resistant tuberculosis takes longer and is more complex. In the face of the resurgence of tuberculosis in the world and the rapid emergence of multi drug resistant tuberculosis, it is very important to develop new anti-tuberculosis drugs or new clinical treatment schemes for existing anti mycobacterium drugs. MCE supplies a unique collection of 95 compounds with clear anti-tuberculosis activity. MCE Anti-tuberculosis Compound Library is a useful tool for anti-tuberculosis related research and anti-tuberculosis drug development

Anti-tuberculosis Compound Library

95 compounds

Tuberculosis (TB), usually caused by bacteria (Mycobacterium tuberculosis), is an infectious disease that mainly affects the lungs. According to the statistics of the World Health Organization (WHO), 10 million people suffer from tuberculosis every year, and 1.5 million people die of tuberculosis every year, which makes tuberculosis the number one killer of infectious diseases.

Tuberculosis can be cured through the standard 6-month course of treatment of four kinds of antibiotics. Common drugs include rifampicin and isoniazid. In some cases, TB bacteria do not respond to standard drugs, that is, patients with drug-resistant tuberculosis. The treatment of drug-resistant tuberculosis takes longer and is more complex. In the face of the resurgence of tuberculosis in the world and the rapid emergence of multi drug resistant tuberculosis, it is very important to develop new anti-tuberculosis drugs or new clinical treatment schemes for existing anti mycobacterium drugs.

MCE supplies a unique collection of 95 compounds with clear anti-tuberculosis activity. MCE Anti-tuberculosis Compound Library is a useful tool for anti-tuberculosis related research and anti-tuberculosis drug development

Cat. No.	Product Name	Type

HY-158289

Isoniazid-KLH	Biochemical Assay Reagents
Isoniazid-KLH is one of protein/peptide and small molecule drug conjugates (PDCs), consisting of Isoniazid (HY-B0329) and KLH. PCDs are promising targeted therapeutics with better cell permeability and drug selectivity than antibody-drug conjugates (ADCs). PDCs have been widely used in research on cancer, COVID-19, and metabolic diseases .

HY-161542

Isoniazid/BSA

Biochemical Assay Reagents

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-I0736

Isonicotinic acid	Alkaloids Aloe africana Liliaceae Source classification Other Diseases Pyridine Alkaloids Plants Disease Research Fields	Drug Metabolite Endogenous Metabolite
Isonicotinic acid is a metabolite of Isoniazid. Isoniazid is converted to Isonicotinic acid by hydrazinolysis, with the Isoniazid to Isonicotinic acid biotransformation also to be catalyzed by cytochrome P450 (CYP) enzymes, e.g., CYP2C .

Cat. No.	Product Name	Chemical Structure

HY-B0329S

Isoniazid-d4
Isoniazid-d₄ is the deuterium labeled Isoniazid. Isoniazid (INH) is a proagent and must be activated by a bacterial catalase-peroxidase enzyme KatG. Isoniazid is bactericidal to rapidly dividing mycobacteria and has anti-tuberculostatic activity[1][2][3][4].

HY-I0736S

Isonicotinic acid-d4
Isonicotinic acid-d₄ is the deuterium labeled Isonicotinic acid[1]. Isonicotinic acid is a metabolite of Isoniazid. Isoniazid is converted to Isonicotinic acid by hydrazinolysis, with the Isoniazid to Isonicotinic acid biotransformation also to be catalyzed by cytochrome P450 (CYP) enzymes, e.g., CYP2C[2].

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Natural
Products

Isotope-Labeled Compounds